News stories about ChromaDex (NASDAQ:CDXC) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChromaDex earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.4325326695757 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring CongressKeynote Speaker, Dr … (markets.businessinsider.com)
- Niagen study confirms NAD+ boost, points to future opportunities in blood pressure, arterial stiffness endpoints (nutraingredients-usa.com)
- ChromaDex Corporation (CDXC) – Technical Deep insight (wallstreetmorning.com)
- Analysts who cover ChromaDex Corporation (CDXC) rated it a consensus rating score of 1.5 (analystrecommendation.com)
Several research firms recently issued reports on CDXC. HC Wainwright set a $8.00 price objective on shares of ChromaDex and gave the stock a “buy” rating in a report on Monday. BidaskClub raised shares of ChromaDex from a “sell” rating to a “hold” rating in a report on Friday, February 9th. ValuEngine upgraded shares of ChromaDex from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th. Finally, Zacks Investment Research cut shares of ChromaDex from a “hold” rating to a “sell” rating in a research note on Monday, February 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $7.50.
ChromaDex (NASDAQ:CDXC) last released its earnings results on Thursday, March 8th. The company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The firm had revenue of $7.53 million during the quarter, compared to analysts’ expectations of $7.50 million. ChromaDex had a negative net margin of 48.68% and a negative return on equity of 52.15%. equities research analysts anticipate that ChromaDex will post -0.14 EPS for the current year.
In related news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $6.52, for a total transaction of $185,031.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Frank L. Jaksch, Jr. sold 24,578 shares of the stock in a transaction on Tuesday, March 27th. The shares were sold at an average price of $4.60, for a total transaction of $113,058.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,431 shares of company stock valued at $300,270. Corporate insiders own 11.59% of the company’s stock.
WARNING: This piece was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://baseballnewssource.com/2018/04/05/chromadex-cdxc-getting-somewhat-positive-media-coverage-report-finds/2028638.html.
ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.